Ben has extensive experience in healthcare and life sciences consulting. He specializes in guiding life sciences organizations across therapeutic areas to optimize their research and development portfolio value, capture new market opportunities and thrive in a disruptive clinical and regulatory environment.
Ben leads the strategy service line for Huron’s life sciences business, working with leaders to build strategies that address their most complex business challenges. He has advised a diverse set of organizations across the industry, from multinational biopharmaceutical firms to privately held biotechnology startups and their investors.
Ben specializes in helping clients allocate R&D investments based on rigorous and transparent early and mid-stage asset, portfolio, and indication prioritization. Over the course of his career, he has worked across therapeutic areas to identify future growth opportunities amid evolving clinical landscapes; identify and vet licensing, merger and acquisition opportunities; assess and evolve organizational business models; and oversee multigeography commercial assessment and franchise planning.
Prior to joining Huron, Ben was a consultant with Frankel Group. He previously worked for Deloitte in the healthcare and life sciences practice of their strategy and operations group.